IP Library Granted Patent US 12,458,570
Granted Patent B2
US 12,458,570 · App. 18/329,969 · Granted Nov 4, 2025

Semisolid oral dispersions comprising active agents

Inventors: Paul Albert Sagel (Mainville, OH); Jayanth Rajaiah (Loveland, OH); Michael David Curtis (Mason, OH)
Assignee: The Procter & Gamble Company
A61K8/22A61K8/20A61K8/21A61K8/31A61K8/345A61K8/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,458,570
App. No.
18/329,969
Granted
Nov 4, 2025
Kind
B2
Abstract

A method for whitening teeth is provided where the method includes contacting at least one tooth surface with a semisolid oral dispersion. The semisolid oral dispersion may include solid hydrophilic active agent particles, where at least about 20 parts, by weight, of the solid hydrophilic active agent particles are soluble in about 100 parts, by weight, of water or the solid hydrophilic active agent particles swell by at least about 50% upon contact with water, and at least about 60%, by weight of the semisolid oral dispersion, of a semisolid hydrophobic phase.

Claims (20)

1 . A method for whitening teeth comprising contacting at least one tooth surface with a semisolid oral dispersion, the semisolid oral dispersion comprising:

a) solid hydrophilic active agent particles comprising a bleaching agent, wherein at least about 50 parts by weight of the solid hydrophilic active agent particles are soluble in about 100 parts by weight of water or the solid hydrophilic active agent particles swell by at least about 50% upon contact with water; and

b) at least about 60%, by weight of the semisolid oral dispersion, of a semisolid hydrophobic phase.

2 . The method of claim 1 , further comprising directing electromagnetic radiation with one or more wavelengths in the range from about 200 nm to about 1700 nm towards the at least one tooth.

3 . The method of claim 1 , wherein the solid hydrophilic active agent particles comprise healing agent, anticalculus agent, anticaries agent, antimicrobial agent, dentinal desensitizing agent, anesthetic agent, antifungal agent, coolant, anti-inflammatory agent, selective H- 2 antagonist, nutrient, erythritol, probiotic, or mixtures thereof.

4 . The method of claim 3 , wherein the healing agent comprises hyaluronic acid or salts thereof, glucosamine or salts thereof, allantoin, curcumin, D-panthenol, niacinamide, ellagic acid, flavanoids, vitamin E, ubiquinone, or combinations thereof.

5 . The method of claim 3 , wherein the anticalculus agent comprises polyphosphate, polyamino propane sulfonic acid, polyolefin sulfonate, polyvinyl phosphate, polyolefin phosphate, diphosphonate, phosphonoalkane carboxylic acid, polyphosphonate, polyvinyl phosphonate, polyolefin phosphonate, polypeptide, salts thereof, or combinations thereof.

6 . The method of claim 3 , wherein the antimicrobial agent comprises triclosan, 5-chloro-2-(2,4-dichlorophenoxy)-phenol, chlorhexidine, alexidine, hexetidine, sanguinarine, benzalkonium chloride, salicylanilide, domiphen bromide, cetylpyridinium chloride, tetradecylpyridinium chloride, N-tetradecyl-4-ethylpyridinium chloride, octenidine, delmopinol, octapinol, piperidino compound, or combinations thereof.

7 . The method of claim 3 , wherein the antimicrobial agent comprises an essential oil, the essential oil comprising citral, geranial, menthol, eucalyptol, thymol, methyl salicylate, or combinations thereof.

8 . The method of claim 3 , wherein the anticaries agent comprises xylitol, fluoride, or combinations thereof.

9 . The method of claim 3 , wherein the coolant comprises desensitizing agent, numbing agent, or combinations thereof.

10 . The method of claim 3 , wherein the anti-inflammatory agent comprises non-steroidal anti-inflammatory agent, the non-steroidal anti-inflammatory agent comprising acetylsalicylic acid, ketorolac, flurbiprofen, ibuprofen, naproxen, indomethacin, ketoprofen, piroxicam, meclofenamic acid, or combinations thereof.

11 . The method of claim 3 , wherein the anti-inflammatory agent comprises COX- 2 inhibitor, the COX- 2 inhibitor comprising valdecoxib, celecoxib, rofecoxib, or combinations thereof.

12 . The method of claim 3 , wherein the solid hydrophilic active agent particles comprise urea peroxide, polyvinyl pyrrolidone complexed with hydrogen peroxide, or combinations thereof.

13 . The method of claim 1 , wherein the solid hydrophilic active agent particles are insoluble in the semisolid hydrophobic phase, and the semisolid hydrophobic phase is insoluble in water.

14 . The method of claim 1 , wherein the semisolid oral dispersion has a cone penetration consistency value of from about 25 to about 300.

15 . The method of claim 1 , wherein the semisolid hydrophobic phase has a cone penetration consistency value of from about 25 to about 300.

16 . The method of claim 1 , wherein the semisolid oral dispersion has a drop melting point of from about 40° C. to about 80° C.

17 . The method of claim 1 , wherein the semisolid hydrophobic phase comprises mineral oil thickened with wax, mineral oil thickened with polyethylene, petrolatum, or combinations thereof.

18 . The method of claim 1 , wherein the semisolid oral dispersion has a bleaching efficacy of at least about 1, and the semisolid oral dispersion has a ratio of the bleaching efficacy to the weight percentage of hydrophilic bleaching agent particles present in the semisolid oral dispersion of at least about 1.

Continuity (3)
Division 16842806 · Apr 8, 2020
Provisional Application 62834684 · Apr 16, 2019
Related Publication 20230310286A1 · Oct 5, 2023
References Cited (117)
US 1863116A · Heymann · 1932 [cited by applicant]
US 4132771A · Schreiber et al. · 1979 [cited by applicant]
US 4198394A · Faunce · 1980 [cited by applicant]
US 4348378A · Kosti · 1982 [cited by applicant]
US 4992258A · Mason · 1991 [cited by applicant]
US 5054582A · Aracil · 1991 [cited by applicant]
US 5077047A · Biss et al. · 1991 [cited by applicant]
US 5674436A · Breitenbach · 1997 [cited by applicant]
US 5735942A · Litkowski et al. · 1998 [cited by applicant]
US 5840220A · Akamatsu et al. · 1998 [cited by applicant]
US 6102254A · Ross · 2000 [cited by applicant]
US 6343933B1 · Montgomery · 2002 [cited by applicant]
US 6382524B1 · James · 2002 [cited by applicant]
US 7304020B1 · Tananko et al. · 2007 [cited by applicant]
US 8623388B2 · Rajaiah · 2014 [cited by applicant]
US 10849729B2 · Sagel · 2020 [cited by examiner]
US 11147753B2 · Rajaiah et al. · 2021 [cited by applicant]
US 11224760B2 · Sagel · 2022 [cited by examiner]
US 11413127B2 · Sagel · 2022 [cited by examiner]
US 11559473B2 · Sagel · 2023 [cited by examiner]
US 11607300B2 · Sagel · 2023 [cited by examiner]
US 11712408B2 · Sagel et al. · 2023 [cited by applicant]
US 11872099B2 · Sagel · 2024 [cited by examiner]
US 12059317B2 · Sagel · 2024 [cited by examiner]
US 20020034479A1 · Green · 2002 [cited by applicant]
US 20020156130A1 · Melman · 2002 [cited by applicant]
US 20030198605A1 · Montgomery · 2003 [cited by examiner]
US 20040101489A1 · Nathoo · 2004 [cited by applicant]
US 20040105823A1 · Kamasaka · 2004 [cited by applicant]
US 20050008584A1 · Montgomery · 2005 [cited by examiner]
US 20050036958A1 · Feng · 2005 [cited by applicant]
US 20050084826A1 · Pilaro · 2005 [cited by applicant]
US 20050137109A1 · Quan et al. · 2005 [cited by applicant]
US 20050143274A1 · Ghosh et al. · 2005 [cited by applicant]
US 20070098650A1 · Miller et al. · 2007 [cited by applicant]
US 20070202059A1 · Longo et al. · 2007 [cited by applicant]
US 20080274067A1 · Chaffer · 2008 [cited by applicant]
US 20080292565A1 · Tung · 2008 [cited by applicant]
US 20090238776A1 · Baig · 2009 [cited by applicant]
US 20100304238A1 · Ku et al. · 2010 [cited by applicant]
US 20110094415A1 · Rajaiah et al. · 2011 [cited by applicant]
US 20120258053A1 · Patel · 2012 [cited by examiner]
US 20120301522A1 · Prosise et al. · 2012 [cited by applicant]
US 20130209374A1 · Cune · 2013 [cited by applicant]
US 20140100303A1 · Rajaiah et al. · 2014 [cited by applicant]
US 20140322666A1 · Chen et al. · 2014 [cited by applicant]
US 20140336272A1 · Bekker · 2014 [cited by examiner]
US 20150258067A1 · Kokkonen et al. · 2015 [cited by applicant]
US 20150366778A1 · Boyd · 2015 [cited by applicant]
US 20170172864A1 · Evans · 2017 [cited by applicant]
US 20180133119A1 · Rajaiah · 2018 [cited by applicant]
US 20180133120A1 · Rajaiah · 2018 [cited by applicant]
US 20180133121A1 · Rajaiah · 2018 [cited by applicant]
US 20180133123A1 · Rajaiah · 2018 [cited by applicant]
US 20180133128A1 · Rajaiah · 2018 [cited by applicant]
US 20180133502A1 · Rajaiah · 2018 [cited by applicant]
US 20180140516A1 · Rajaiah · 2018 [cited by applicant]
US 20180168973A1 · Hassan · 2018 [cited by examiner]
US 20180168993A1 · Yuan · 2018 [cited by applicant]
US 20180243178A1 · Nesta · 2018 [cited by applicant]
US 20190054003A1 · Evans · 2019 [cited by applicant]
US 20200330206A1 · Sagel et al. · 2020 [cited by applicant]
US 20200330340A1 · Sagel et al. · 2020 [cited by applicant]
US 20200330341A1 · Sagel et al. · 2020 [cited by applicant]
US 20200330784A1 · Sagel et al. · 2020 [cited by applicant]
US 20200397547A1 · Sagel et al. · 2020 [cited by applicant]
US 20200397548A1 · Sagel et al. · 2020 [cited by applicant]
US 20200397549A1 · Sagel et al. · 2020 [cited by applicant]
US 20200397550A1 · Sagel et al. · 2020 [cited by applicant]
US 20230157933A1 · Rajaiah et al. · 2023 [cited by applicant]
EP 3315117A1 · 2016 [cited by applicant]
EP 3315118A1 · 2016 [cited by applicant]
EP 3315119A1 · 2016 [cited by applicant]
EP 3315171A1 · 2016 [cited by applicant]
EP 3315172A1 · 2016 [cited by applicant]
EP 3315173A1 · 2016 [cited by applicant]
WO 8102670A1 · 1981 [cited by applicant]
WO 2006138550A1 · 2006 [cited by applicant]
WO 2013095369A2 · 2011 [cited by applicant]
WO 2015195140A1 · 2015 [cited by applicant]
WO 2017106588A1 · 2016 [cited by applicant]
WO 2017048216A1 · 2017 [cited by applicant]
WO 2018081001A1 · 2017 [cited by applicant]
WO 2018081004A3 · 2017 [cited by applicant]
G.E. Salvi and N.P. Lang. “The Effects of Non-Steroidal Anti-Inflammatory Drugs (Selective and Non-Selective) on the Treatment of Periodontal Diseases.” Current Pharmaceutical Design, vol. 11, 2005, pp. 1757-1769. (Year… [cited by examiner]
All Office Actions; U.S. Appl. No. 18/760,144, filed Jul. 1, 2024. [cited by applicant]
Unpublished U.S. Appl. No. 18/760,144, filed Jul. 1, 2024, to Paul Albert Sagel et al. [cited by applicant]
“Brush & Bleach Teeth Whitening Kit” Anonymous Database GNPD MINTEL; Feb. 22, 2018, retrieved from www.gnpd.com abstract. [cited by applicant]
“Extreme White Fresh Mint Whitening Toothpaste” Anonymouse, Database GNPD MINTEL, Nov. 15, 2018; retrieved from www.gnpd.com—abstract. [cited by applicant]
All Office Actions, U.S. Appl. No. 17/014,208, filed Sep. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 16/842,799, filed Apr. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 16/842,800, filed Apr. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 16/842,806, filed Apr. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 17/008,681, filed Sep. 1, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 17/014,180, filed Sep. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 17/014,225, filed Sep. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 16/842,798, filed Apr. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 16/842,804, filed Apr. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 16/842,797, filed Apr. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 16/842,802, filed Apr. 8, 2020. [cited by applicant]
All Office Actions; U.S. Appl. No. 18/100,201, filed Jan. 23, 2023. [cited by applicant]
Amazon.com: Sorbitol Solution USP 70% WIW Laxative 16 oz. (473mL): Laxatives : Health & Household. “https://www.amazon.com/SORBITOL-Solution-USP-Laxative-473mL/dp/BOO1V900RO” accessed Oct. 26, 2022, pp. 1-8. [cited by applicant]
Dubbs et al.,“Solubility of Vitamin E (r-Tocopherol) and Vitamin K3 (Menadione) in Ethanol-Water Mixture”, Journal of Chemical Engineering Data, vol. 43, 1998, pp. 590-591. [cited by applicant]
EP Search Report CM5055F for 19169614.5-1114 dated Oct. 28, 2019. [cited by applicant]
EP Search Report CM5056F for 19169615.2-1114 dated Oct. 28, 2019. [cited by applicant]
EP Search Report CM5057F for 19169621.0-1114 dated Jul. 17, 2019. [cited by applicant]
EP Search Report CM5059F for 19169629.3-1114 dated Nov. 11, 2019. [cited by applicant]
EP Search Report CM5060F for 19169630.1-1114 dated Jul. 17, 2019. [cited by applicant]
EP Search Report CM5061F for 19169637.6-1114 dated Nov. 11, 2019. [cited by applicant]
EP Search Report for CM5058F—19169624.4-1114 dated Nov. 11, 2019. [cited by applicant]
Hawley's Condensed Chemical Dictionary, 16th edition, 2016, pp. 1025-1128. [cited by applicant]
Ira L. Shannon and Warren R. Hester. “The Effect of an Aqueous Stannous Fluoride Prophylaxis Paste on Enamel Solubility.” United States Air Force, Technical Documentary Report No. SAM-TDR-62-79, dated Jun. 1962, pp. i-i… [cited by applicant]
Jose L. Toro. “Semi-Solids: A Regulatory Perspective.” https://www.contractpharma.com/issues/2018-06-01/view_fda-watch/semi-solid-dosage-forms/ accessed Sep. 13, 2021, pp. 1-9. (Year: 2021). [cited by applicant]
Lazarchik et al. “Use of tray-applied 10 percent carbamide peroxide gels for improving oral health in patients with special-care needs”, JADA, vol. 141, pp. 639-646, Jun. 2010. [cited by applicant]
McKillop Et Al. “Sodium Perborate and Sodium Percarbonate: Cheap, Safe and Versatile Oxidising Agents for Organic Synthesis”, Tetrahedron vol. 51, No. 22, 1995, pp. 6145-6166. [cited by applicant]
Solvay Brochure IXPER(R) C calcium peroxide. www.solvay.com, May 22, 2020. [cited by applicant]
Maged Younes et al. “Re-evaluation of stannous chloride (E 512) as food additive” EFSA Journal, May 17, 2018, 301 pages. [cited by applicant]